z-logo
open-access-imgOpen Access
Azathioprin effect on immunologic parameters of patients with newly detected insulin-dependent diabetes mellitus
Author(s) -
М. Ш. Шамхалова,
I. A. Abugova,
P. I. Shishko,
И И Дедов,
Л. В. Козлов,
Vladimir Alyoshkin,
M. N. Rozina
Publication year - 1993
Publication title -
problemy èndokrinologii
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.124
H-Index - 5
eISSN - 2308-1430
pISSN - 0375-9660
DOI - 10.14341/probl11931
Subject(s) - diabetes mellitus , contraindication , medicine , insulin , immunity , immunology , immune system , cytotoxic t cell , endocrinology , cellular immunity , biology , in vitro , pathology , biochemistry , alternative medicine
Azathioprin immunosuppressive therapy prolongs remissions and stimulates residual p-cell function, suppresses insulin antibody production, reduces the activity of the complement and CH50 components, reduces initially increased cellular immunity parameters (total T and В cell counts, T helper to T inductor ratio, and the count of DR carrier cells) in patients with newly detected insulin-dependent diabetes mellitus; this makes this drug effective at the firts stages of the disease. When selecting patients for immunosuppressive therapy the following immunity parameters should be examined: complement status, total counts of T and В lymphocytes, T-helper-in- ductor/T-suppressor-cytotoxic immunoregulation index, DR carrier cell counts. Reduced levels thereof are a contraindication against immunosuppressant therapy. Male patients with insulindependent diabetes mellitus debut at the age of over 25 are particularly susceptible to immunosuppressive therapy with azathioprin.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here